NTRB, NTRBW · CIK 0001676047 · operating
# NutriBulk Inc. (NTRB)
Based in Orlando, Florida, this development-stage biotechnology company focuses on transdermal pharmaceutical delivery systems. The company's primary pipeline consists of abuse-deterrent and non-abuse-deterrent transdermal products, with AVERSA fentanyl as its lead candidate—a transdermal system designed for chronic pain management in patients requiring continuous opioid therapy. The company is also developing AVERSA buprenorphine and AVERSA methylphenidate formulations, alongside other transdermal pharmaceutical candidates.
The company does not currently generate meaningful product revenues, operating primarily on development and research activities. Nutriband maintains a commercial development and clinical supply partnership with Kindeva Drug Delivery to support its product development efforts. The company was incorporated in Nevada in 2016 and operates from its Orlando headquarters with a small operational footprint typical of early-stage development companies.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.99 | $-0.99 | -43.5% | |
| 2024 | $-0.69 | $-0.69 | -30.2% | |
| 2023 | $-0.53 | $-0.53 | +43.6% | |
| 2022 | — | $-0.94 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-01-31 | 2025-04-28 | 0001213900-25-036201 | SEC ↗ |
| 2024-01-31 | 2024-05-01 | 0001213900-24-037996 | SEC ↗ |
| 2023-01-31 | 2023-04-26 | 0001213900-23-032682 | SEC ↗ |
| 2022-01-31 | 2022-04-29 | 0001213900-22-022425 | SEC ↗ |
| 2021-01-31 | 2021-04-02 | 0001213900-21-019991 | SEC ↗ |
| 2020-01-31 | 2020-04-14 | 0001213900-20-009139 | SEC ↗ |
| 2019-01-31 | 2019-04-19 | 0001213900-19-006792 | SEC ↗ |
| 2018-01-31 | 2018-05-01 | 0001213900-18-005302 | SEC ↗ |
| 2017-01-31 | 2017-05-08 | 0001213900-17-004683 | SEC ↗ |